These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

608 related items for PubMed ID: 30027419

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. High detection rate in [18F]PSMA-1007 PET: interim results focusing on biochemical recurrence in prostate cancer patients.
    Watabe T, Uemura M, Soeda F, Naka S, Ujike T, Hatano K, Sasaki H, Kamiya T, Shimosegawa E, Kato H, Cardinale J, Tateishi U, Nonomura N, Giesel FL.
    Ann Nucl Med; 2021 Apr; 35(4):523-528. PubMed ID: 33661475
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Head-to-Head Comparison of 18F-Prostate-Specific Membrane Antigen-1007 and 18F-Fluorocholine PET/CT in Biochemically Relapsed Prostate Cancer.
    Witkowska-Patena E, Giżewska A, Dziuk M, Miśko J, Budzyńska A, Walęcka-Mazur A.
    Clin Nucl Med; 2019 Dec; 44(12):e629-e633. PubMed ID: 31689286
    [Abstract] [Full Text] [Related]

  • 25. Clinical Factors That Influence Repeat 68Ga-PSMA-11 PET/CT Scan Positivity in Patients with Recurrent Prostate Cancer Under Observation After a Negative 68Ga-PSMA-11 PET/CT Scan: A Single-Center Retrospective Study.
    Thin P, Hotta M, Gafita A, Grogan T, Czernin J, Calais J, Sonni I.
    J Nucl Med; 2024 Oct 01; 65(10):1571-1576. PubMed ID: 39168522
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. 18F-PSMA-1007 multiparametric, dynamic PET/CT in biochemical relapse and progression of prostate cancer.
    Sachpekidis C, Afshar-Oromieh A, Kopka K, Strauss DS, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A.
    Eur J Nucl Med Mol Imaging; 2020 Mar 01; 47(3):592-602. PubMed ID: 31728588
    [Abstract] [Full Text] [Related]

  • 29. Retrospective correlation of 68ga-psma uptake with clinical parameters in prostate cancer patients undergoing definitive radiotherapy.
    Onal C, Torun N, Oymak E, Guler OC, Reyhan M, Yapar AF.
    Ann Nucl Med; 2020 Jun 01; 34(6):388-396. PubMed ID: 32221791
    [Abstract] [Full Text] [Related]

  • 30. The role of (68Ga)PSMA I&T in biochemical recurrence after radical prostatectomy: detection rate and the correlation between the level of PSA, Gleason score, and the SUVmax.
    Yilmaz U, Komek H, Can C, Altindag S.
    Ann Nucl Med; 2019 Aug 01; 33(8):545-553. PubMed ID: 31069696
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Comparison of 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence.
    Calais J, Fendler WP, Herrmann K, Eiber M, Ceci F.
    J Nucl Med; 2018 May 01; 59(5):789-794. PubMed ID: 29242404
    [Abstract] [Full Text] [Related]

  • 33. The use of 68  Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer.
    Meredith G, Wong D, Yaxley J, Coughlin G, Thompson L, Kua B, Gianduzzo T.
    BJU Int; 2016 Oct 01; 118 Suppl 3():49-55. PubMed ID: 27659411
    [Abstract] [Full Text] [Related]

  • 34. Evaluation of 18F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy.
    Zhou X, Jiang X, Liu L, Wang X, Li C, Yao Y, Kou Y, Shen J, Shen T, Li Z, Yang S, Zhou S, Liao H, Luo Z, Wu X, Chen S, Cheng Z.
    Transl Oncol; 2022 Jan 01; 15(1):101292. PubMed ID: 34837847
    [Abstract] [Full Text] [Related]

  • 35. Changes in Management After 18F-DCFPyL PSMA PET in Patients Undergoing Postprostatectomy Radiotherapy, with Early Biochemical Response Outcomes.
    Ng M, Guerrieri M, Wong LM, Taubman K, Sutherland T, Benson A, Byrne G, Koschel S, Yap K, Starmans M, Ong G, Macleod C, Foo M, Chao M.
    J Nucl Med; 2022 Sep 01; 63(9):1343-1348. PubMed ID: 35058320
    [Abstract] [Full Text] [Related]

  • 36. Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy.
    Rauscher I, Düwel C, Haller B, Rischpler C, Heck MM, Gschwend JE, Schwaiger M, Maurer T, Eiber M.
    Eur Urol; 2018 May 01; 73(5):656-661. PubMed ID: 29358059
    [Abstract] [Full Text] [Related]

  • 37. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S, Coronado-Poggio M, García-Vicente AM, García-Garzón JR, Alonso-Farto JC, de la Jara AC, Maldonado-Suárez A, Rodríguez-Fernández A.
    BJU Int; 2015 Jun 01; 115(6):874-83. PubMed ID: 25307619
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Matched-Pair Comparison of 68Ga-PSMA-11 PET/CT and 18F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy.
    Rauscher I, Krönke M, König M, Gafita A, Maurer T, Horn T, Schiller K, Weber W, Eiber M.
    J Nucl Med; 2020 Jan 01; 61(1):51-57. PubMed ID: 31253741
    [Abstract] [Full Text] [Related]

  • 40. Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients.
    Natarajan A, Agrawal A, Murthy V, Bakshi G, Joshi A, Purandare N, Shah S, Puranik A, Rangarajan V.
    World J Nucl Med; 2019 Jan 01; 18(3):244-250. PubMed ID: 31516367
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.